A
19 HbA1c – Hemoglobina glicada A1c
Figura 2 – Relação da HbA1c média com o tempo de utilização de Perfusão Subcutânea
20 CT – Colesterol total, TG – Triglicerídeos, HDL-C – Colesterol de lipoproteínas de alta densidade, LDL-C –
Colesterol de lipoproteínas de baixa densidade
21
CT – Colesterol total, TG – Triglicerídeos, HDL-C – Colesterol de lipoproteínas de alta densidade, LDL-C –
Colesterol de lipoproteínas de baixa densidade
Figura 4 – Evolução dos parâmetros do perfil lipídico com a idade 60 40 Idade (anos) 18 17 16 15 14 13 12 11 10 200 180 160 140 120 100 80 CT LDL-C TG HDL-C mg/dL
A
B
D
E
C
22 TG – Triglicerídeos, HDL-C – Colesterol de lipoproteínas de alta densidade
23 Bibliografia
1. Levitsky L, Misra M. Complications and screening in children and adolescents with type 1 diabetes mellitus. Up to date, 2018.
2. Demirel F, Tepe D, Kara O, Esen I. Microvascular complications in adolescents with type 1 diabetes mellitus. J Clin Res Pediatr Endocrinol, 2013; 5:145-9.
3. International Diabetes Federation. IDF Diabetes Atlas: 7ª edição, 2015.
4. Observatório Nacional da Diabetes. Diabetes Factos e Números – O ano de 2015: 8.ª Edição, 2016.
5. Narayan K, Boyle J, Thompson T, Sorensen S, Williamson D, Lifetime risk for diabetes mellitus in United States. JAMA, 2003; 290: 1884-90.
6. Levitsky L, Misra M. Management of type 1 diabetes mellitus in children and adolescentes. Up to date, 2018.
7. Ferranti S, Newburger J. Dyslipidemia in children: Definition, screening, and diagnosis. Up to date, 2018.
8. Matheus A, Cobas R, Gomes M. Dislipidemias no Diabetes Melito Tipo 1: Abordagem Atual. Arq Bras Endrocrinol Metab, 2008; 52(2): 334-9.
9. Hartz J, Ferranti S, Gidding S. Hypertriglyceridemia in Diabetes Mellitus: Implications for Pediatric Care. Journal of the Endocrine Society, 2018: 2(6): 497-512.
10. Ferranti S, Newburger J. Overview of the management of the child at risk for atherosclerosis. Up to date, 2017.
11. Carneiro L, Lacerda E, Costa V, et al. Perfil lipidico de crianças e adolescentes com Diabetes Mellitus tipo 1. Nutr. clín. diet. Hosp, 2017; 37(4):23-28
12. Bulum T, Kolaric B, Duvnjak L. Lower levels of total HDL and HDL3 cholesterol are associated with albuminuria in normoalbuminuric Type 1 diabetic patients. J Endocrinol Invest, 2013; 36:574-8
13. Direção-Geral da Saúde. Circular normativa nº 033/2011, 06/12/2012. Prescrição e Determinação da Hemoglobina Glicada A1c.
14. Brownlee M, Hirsch I. Glycemic variability: a hemoglobin A1c-independent risk factor for diabetic complications. JAMA, 2006; 295:1707.
15. DiMeglio L, Acerini CL, Codner E, et al. ISPAD Clinical Practice Consensus Guidelines 2018: Glycemic control targets and glucose monitoring for children, adolescents, and young adults with diabetes. Pediatr Diabetes, 2018; 19(27):105–114.
16. Direção-Geral da Saúde. Saúde Infantil e Juvenil - Programa Nacional, 2012.
17. Direção-Geral da Saúde. Programa Nacional para a Diabetes, 2017.
18. Karges B, Schwandt A, Heidtmann B, et al. Association of Insulin Pump Therapy vs Insulin Injection Therapy With Severe Hypoglycemia, Ketoacidosis, and Glycemic Control Among Children, Adolescents, and Young Adults With Type 1 Diabetes. JAMA, 2017; 318:1358.
19. Pańkowska E, Błazik M, Dziechciarz P, et al. Continuous subcutaneous insulin infusion vs. multiple daily injections in children with type 1 diabetes: a systematic review and meta- analysis of randomized control trials. Pediatr Diabetes, 2009; 10:52.
20. Despacho n.º 13277/2016, Diário da República, 2.ª série. N.º 213 (07/11/2016); 33021- 33022.
21. Maahs D, Maniatis A, Nadeau K, et al. Total cholesterol and high-density lipoprotein levels in pediatric subjects with type 1 diabetes mellitus. J Pediatr, 2005; 147:544.
22. Zabeen B, Balsa A, Islam N, Parveen M, Nahar J, Azad K. Lipid Profile in Relation to Glycemic Control in Type 1 Diabetes Children and Adolescents in Bangladesh. Indian J Endocrinol Metab, 2018; 22:89-92.
23. Golle C, Bernardes S, Nunes L. Prevalência de fatores de risco cardiovasculares em adolescentes portadores de diabetes mellitus tipo 1. Adolesc. Saude Rio de Janeiro, 2018; 15(1): 26-33.
24
24. Monnier L, Colette C, Wojtusciszyn A, et al. Toward defining the threshold between low and high glucose variability in diabetes. Diabetes Care, 2017; 40:832–838.
25. Beck R, Bergenstal R, Cheng P, et al. The Relationships Between Time in Range, Hyperglycemia Metrics, and HbA1c. Journal of Diabetes Science and Technology, 2019; 00(0):1-13.
26. Guy J, Ogden L, Wadwa R, et al. Lipid and lipoprotein profiles in youth with and without type 1 diabetes: the SEARCH for Diabetes in Youth case-control study. Diabetes Care. 2009; 32(3):416–420.
27. Kushner P, Cobble M. Hypertriglyceridemia: the importance of identifying patients at risk.Postgrad Med, 2016; 128(8):848–858.
28. Subramanian S, Chait A. Hypertriglyceridemia secondary to obesity and diabetes. Biochim Biophys Acta. 2012; 1821(5):819–825.
29. Adiels M, Olofsson S, Taskinen M, Boren J. Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. Arterioscler Thromb Vasc Biol, 2008; 28(7):1225–1236.
30. Cullen P. Evidence that triglycerides are an independent coronary heart disease risk factor. Am J Cardiol, 2000;86(9):943–949.
31. Silveira A, Gomes K, Fernandes A, Domingueti C. Avaliação de fatores de risco para dislipidemia em pacientes diabéticos tipo 1. RSC online, 2017; 6(1): 33- 48.
32. Castro S, Faria-Neto H, Gomes M. Association of postprandial hyperglycemia with in vitro LDL oxidation in nonsmoking patients with type 1 diabetes– a cross-sectional study. Rev Diabetic Stud, 2005;2(3):157-64.
33. Skyrme-Jones R, O’Brien R, Luo M, Meredith I. Endothelial Vasodiltators function is related to low-density lipoprotein particle size and low-density lipoprotein vitamin E content in type 1 diabetes. J Am Coll Cardiol, 2000; 35:292-9.
34. Haney E, Huffman L, Bougatsos C, Freeman M, Steiner R, Nelson H. Screening and treatment for lipid disorders in children and adolescents: systematic evidence review for the US Preventive Services Task Force. Pediatrics, 2007; 120(1): e189-207.
35. Centers for Disease Control and Prevention (CDC). Prevalence of abnormal lipid levels among youths --- United States, 1999-2006. MMWR Morb Mortal Wkly Rep, 2010; 59:29.
36. Purnell J, Hokanson J, Marcovina S, Steffes M, Cleary P, Brunzell J. Effect of excessive weight-gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from DCCT. Diabetes control and complications trial. JAMA, 1998; 280(2):140-6.
37. Reh C, Mittelman S, Wee C, Shah A, Kaufman F, Wood J. A longitudinal assessment of lipids in youth with type 1 diabetes. Pediatric Diabetes, 2011; 12:365–371.
38. Maahs D, Wadwa R, McFann K et al. Longitudinal lipid screening and use of lipid-lowering medications in pediatric type 1 diabetes. J Pediatr, 2007;150 (2):146–150.
39. Salgado P, Penido M, Júnior A, Oliveira M, Santana N, Silva A. Abordagem da Nefropatia Diabética em Pediatria. Rev Med Minas Gerais, 2006; 15(4): 234-41.
40. Galler A, Müller G, Schinzel R, Kratzsch J, Kiess W, Münch G. Impact of metabolic control and serum lipids on the concentration of advanced glycation end products in the serum of children and adolescents with type 1 diabetes, as determined by fluorescence spectroscopy and nepsilon-(carboxymethyl)lysine ELISA. Diabetes Care, 2003;26:2609-15.
41. Soedamah-Muthu S, Chaturvedi N, Witte D, et al. Relationship Between Risk Factors and Mortality in Type 1 Diabetic Patients in Europe - The EURODIAB Prospective Complications Study (PCS). Diabetes Care,2008; 31 (7):1360–1366
42. Molitch M, Rupp D, Carnethon M. Higher levels of HDL cholesterol are associated with a decreased likelihood of albuminúria in patients with long-standing type 1 diabetes. Diabetes Care, 2006; 29:78-82.
43. Nambam B, DuBose S, Nathan B, et al. Therapeutic inertia: underdiagnosed and undertreated hypertension in children participating in the T1D Exchange Clinic Registry. Pediatr Diabetes, 2016; 17:15.